Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

93.40 -0.64 (-0.68%)
Streaming Delayed Price Updated: 10:12 AM EDT, Jul 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 40,875
Open 92.76
Bid (Size) 93.31 (100)
Ask (Size) 93.64 (200)
Prev. Close 94.04
Today's Range 92.59 - 94.68
52wk Range 28.66 - 94.77
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Cash-Heavy Stocks with Questionable Fundamentals
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
Via StockStory
News headline image
3 High-Flying Stocks We Steer Clear Of
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta... 
Via StockStory

Performance

YTD
+144.5%
+144.5%
1 Month
+27.4%
+27.4%
3 Month
+124.0%
+124.0%
6 Month
+161.0%
+161.0%
1 Year
+38.3%
+38.3%

More News

Read More
News headline image
3 Unpopular Stocks We Steer Clear Of
Via StockStory
News headline image
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via Business Wire
Corcept Therapeutics (NASDAQ:CORT) Revenue Miss Leads to Q1 Net Loss, But Guidance Upgrade and Lifyorli Launch Signal Strong Momentum ↗
Via Chartmill
News headline image
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
1 of Wall Street’s Favorite Stocks with Exciting Potential and 2 We Question
Via StockStory
News headline image
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
3 Reasons to Sell CORT and 1 Stock to Buy Instead
Via StockStory
News headline image
3 High-Flying Stocks We Think Twice About
Via StockStory
News headline image
Corcept (CORT) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Corcept (CORT) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Corcept (CORT) Q1 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Corcept (CORT) Q2 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures
Via StockStory
News headline image
Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates
Via StockStory
News headline image
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Earnings: What To Look For From CORT
Via StockStory
Topics Artificial Intelligence
News headline image
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
CORCEPT DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORT
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
1 Cash-Producing Stock for Long-Term Investors and 2 We Ignore
Via StockStory

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 93.40
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 07/08/26 10:12 AM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 10.83B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 11B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.